Cancer Pharmacology Lab is an “AIRC Startup Unit” which aims at improving cancer therapeutics either by the development/optimization of new antitumor agents and more effective drug combinations (including chemotherapy, immunotherapy and targeted therapy) or by the tailoring of existing and new therapies.
Meet the Team
Our laboratory focuses on how to implement personalized treatment into the clinic. Elucidation of resistance mechanisms to conventional and novel anticancer drugs and on ways to bypass them is studied both in appropriate model systems and in patients.
We published several of our studies in so-called first class journals, such as Cancer Research and Journal of the National Cancer Institute and we have been invited to present our research in international meetings, including AACR, EORTC, ESMO-ECCO, American Pancreas Club and EPC.
We closely collaborates with scientists from various parts of the world, sharing many projects, including analytical methods and preclinical models to integrate multiple endpoints – such as measurement of drug concentration/activity, genomics, and phospho-proteomics.
We give hospitality to master (medical and biology) students, Ph.D. students and post-docs in our laboratory to get them acquainted with biomedical and translational research. Many of them contributed significantly to our research.
- Primary cell cultures
- Novel bioluminescent orthotopic models
- Tissue microarrays
- Genetic profiling
- Targeted therapies and novel combinations
Cancer Pharmacology Lab è un nuovo laboratorio finanziato da una grant di 5 anni dell’AIRC
(Associazione Italiana per la Ricerca sul Cancro) alla Dr.ssa Elisa Giovannetti
. Nel nostro progetto di ricerca useremo delle culture cellulari primarie di tumore del pancreas, un’ampia raccolta di campioni tissutali e nuove metodologie di imaging per valutare l’attività preclinica di nuovi farmaci specifici, e approfondire le conoscenze sulle caratteristiche biologiche e genetiche di questo tumore.
find out more »